Skip to main content
MedPathMedPath Home
Clinical Trials/NCT01488331
NCT01488331
Completed
N/A

A Patient Cohort With Locally Advanced or Metastatic Non-small Cell Lung Cancer Treated With Tarceva (Erlotinib) Monotherapy and Not Progressing After at Least 9 Months

Hoffmann-La Roche0 sites217 target enrollmentJune 2010
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsNon-Squamous Non-Small Cell Lung Cancer

Overview

Phase
N/A
Intervention
Not specified
Conditions
Non-Squamous Non-Small Cell Lung Cancer
Sponsor
Hoffmann-La Roche
Enrollment
217
Primary Endpoint
Progression-free survival
Status
Completed
Last Updated
9 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

This prospective, multi-center, observational study will assess the progression-free survival and safety of patients with locally advanced or metastatic non-small cell lung cancer treated with Tarceva (erlotinib) and not disease progressing after at least 9 months. Data will be collected for 24 months.

Registry
clinicaltrials.gov
Start Date
June 2010
End Date
November 2013
Last Updated
9 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •Adult patients, \>/=18 years of age
  • •Diagnosis of locally advanced or metastatic non-small cell lung cancer (NSCLC, stage III/IV)
  • •Treatment with Tarceva monotherapy and not progressing after at least 9 months at the date of study start

Exclusion Criteria

  • •Not agreeing to be followed-up (for a maximum of 24 months)

Outcomes

Primary Outcomes

Progression-free survival

Time Frame: 24 months

Secondary Outcomes

  • Overall survival(24 months)
  • Treatment compliance of patient(24 months)
  • Best treatment response(24 months)
  • Safety (incidence of adverse events)(24 months)
  • Type of treatment response(24 months)

Similar Trials

Terminated
Phase 3
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer PatientsNeoplasms, BreastCarcinoma of BreastHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastBRCA1 Gene MutationBRCA2 Gene MutationOvarian Neoplasms
NCT01905592Tesaro, Inc.216
Completed
N/A
Observational Study of Bevacizumab [Avastin] in Patients With Metastatic Colorectal Cancer (AVASTART)Colorectal Cancer
NCT01089413Hoffmann-La Roche201
Completed
N/A
ASPET Study: An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced Non-Small Cell Lung Cancer Harbouring EGFR Activating MutationsNon-Squamous Non-Small Cell Lung Cancer
NCT01723878Hoffmann-La Roche144
Active, Not Recruiting
N/A
Risk Factors and Long-term Impact of ICIsMalignant Neoplasm
NCT05754983First Affiliated Hospital Xi'an Jiaotong University1,000
Recruiting
Phase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)Non-Small Cell Lung Cancer (NSCLC)
NCT05920356Amgen750